Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
38.77
-0.54 (-1.37%)
At close: Dec 5, 2025, 4:00 PM EST
38.51
-0.26 (-0.67%)
After-hours: Dec 5, 2025, 7:58 PM EST
Cogent Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | - | - | - | 7.87 | |
| Revenue Growth (YoY) | - | - | - | - | - | -65.02% | |
| Cost of Revenue | - | - | - | - | - | 25.74 | |
| Gross Profit | - | - | - | - | - | -17.87 | |
| Selling, General & Admin | 51.34 | 43.28 | 34.38 | 26.21 | 19.64 | 17.42 | |
| Research & Development | 256.27 | 232.66 | 173.76 | 121.63 | 55.91 | - | |
| Operating Expenses | 307.6 | 275.94 | 208.13 | 147.84 | 75.55 | 17.42 | |
| Operating Income | -307.6 | -275.94 | -208.13 | -147.84 | -75.55 | -35.29 | |
| Interest & Investment Income | 13.07 | 18.09 | 13.08 | 3.99 | 0.47 | 0.14 | |
| Other Non Operating Income (Expenses) | 6.04 | 1.99 | 2.64 | 3.61 | 2.81 | -0.25 | |
| EBT Excluding Unusual Items | -290.26 | -255.86 | -192.41 | -140.24 | -72.27 | -35.39 | |
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 7.49 | |
| Pretax Income | -294.37 | -255.86 | -192.41 | -140.24 | -72.27 | -74.81 | |
| Earnings From Continuing Operations | - | -255.86 | -192.41 | -140.24 | -72.27 | -74.81 | |
| Net Income | -294.37 | -255.86 | -192.41 | -140.24 | -72.27 | -74.81 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 104.4 | |
| Net Income to Common | -294.37 | -255.86 | -192.41 | -140.24 | -72.27 | -179.21 | |
| Shares Outstanding (Basic) | 119 | 104 | 80 | 59 | 39 | 11 | |
| Shares Outstanding (Diluted) | 119 | 104 | 80 | 59 | 39 | 11 | |
| Shares Change (YoY) | 21.79% | 30.36% | 35.54% | 51.89% | 249.52% | 45.42% | |
| EPS (Basic) | -2.47 | -2.46 | -2.41 | -2.38 | -1.87 | -16.17 | |
| EPS (Diluted) | -2.47 | -2.46 | -2.41 | -2.38 | -1.87 | -16.17 | |
| Free Cash Flow | -246.73 | -208.36 | -156.42 | -125.5 | -60.48 | -35.85 | |
| Free Cash Flow Per Share | -2.07 | -2.00 | -1.96 | -2.13 | -1.56 | -3.23 | |
| Gross Margin | - | - | - | - | - | -227.00% | |
| Operating Margin | - | - | - | - | - | -448.34% | |
| Profit Margin | - | - | - | - | - | -2276.81% | |
| Free Cash Flow Margin | - | - | - | - | - | -455.47% | |
| EBITDA | -305.04 | -273.49 | -205.86 | -147 | -75.4 | -34.57 | |
| D&A For EBITDA | 2.56 | 2.45 | 2.27 | 0.84 | 0.15 | 0.72 | |
| EBIT | -307.6 | -275.94 | -208.13 | -147.84 | -75.55 | -35.29 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.